Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07652749

Stellate Ganglion Block and Prognosis of Neurological Function After Subarachnoid Hemorrhage

The incidence of cerebral vasospasm after aneurysm subarachnoid hemorrhage (aSAH) is as high as 70%; cerebral vasospasm（CVS） is closely related to delayed cerebral ischemia （DCI）, which is one of the important reasons for poor outcomes in patients with aSAH.

In recent years, it has been reported that stellate ganglion block(SGB) can effectively alleviate cerebral vasospasm(CVS), reduce cerebral blood flow velocity and increase cerebral perfusion in patients with aneurysm subarachnoid hemorrhage(aSAH)。However, whether the alleviation of CVS after SGB is beneficial to the long-term neurological prognosis has not been confirmed Therefore, a prospective randomized controlled study is needed to further explore the role of SGB block in improving the outcomes of patients with aSAH.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Aneurysmal Subarachnoid Hemorrhage Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Hemorrhage Intracranial Hemorrhages Nervous System Diseases Neurological Prognosis Pathologic Processes Pathological Conditions, Signs and Symptoms Stellate Ganglion Block Subarachnoid Hemorrhage Vascular Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Beijing Tiantan Hospital, Capital Medical University

Beijing, Beijing Municipality, 100070, China

Location contact

Ruquan Han, M.D., Ph.D

CONTACT

[email protected]

8610-59976660

Ruquan Han, M.D., Ph.D

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age range: 18-65 years old;
  • Within 72 hours after onset of aSAH,and planning surgical treatment(aneurysm embolizing or clipping);
  • Preoperative Hunt-Hess grade 2-3
  • Sign informed consent.

Exclusion criteria

  • ASA > grade IV;
  • Patients with posterior circulation aneurysm;
  • Patients with severe systemic hemorrhagic diseases;
  • Patients with trauma and local infection in the nerve block area;
  • Local anatomic structure changes (neck structure changes caused by radiotherapy, chemotherapy and surgery);
  • Allergy to known local anesthetics;
  • Pregnant and lactating women.

Treatment and study plan

Intervention group

Procedure

Prior to the initiation of surgery, a single ultrasound-guided stellate ganglion block was performed on the ipsilateral side of the lesion.The dose and concentration of local anesthesia: 0.5% ropivacaine 5-10ml. Criteria for successful block: the patient developed Horner's syndrome, characterized by miosis, ptosis, eyeball caved in, nasal congestion, conjunctival congestion, reddish face and no sweat on the face

Other names: Stellate ganglion block

Primary outcomes

  1. The modified Rankin Scale (mRS) scores at 90 days

    Time frame: 90 days postoperatively

    The modified Rankin Scale (mRS) is used to evaluate the primary outcome. The scale of mRS is 0 to 6. The best neurological outcome is the mRS with 0, indicating no any symptom left. mRS of 6 is the worst, indicating death. mRS will be evaluated by outcomes assessor who is blinded to the grouping.

Secondary outcomes

  1. The incidence of delayed cerebral ischemia (DCI) during hospitalization

    Time frame: At discharge, an average of 2 weeks

  2. All cause mortality during 90 days after onset

    Time frame: 90 days postoperatively

  3. Length of stay in the intensive care unit and hosipital

    Time frame: At discharge, an average of two weeks

  4. Adverse events during hospitalization

    Time frame: At discharge, an average of 2 weeks

    Myocardial infarction, cardiac arrest, pulmonary embolism, infection, SGB related complications, etc

Study contacts

Contact information is provided by the study sponsor or research team.

Ruquan Han, M.D., Ph.D

CONTACT

[email protected]

8610-59976660

Sponsors and collaborators

Lead sponsor

Beijing Tiantan Hospital

Other

Registry information

Official study title

Effect of Stellate Ganglion Block on the Prognosis of Neurological Function After Subarachnoid Hemorrhage

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Jun 17, 2026
Registry last updated
Jun 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.